An Apolipoprotein A-I Mimetic Peptide Designed with a Reductionist Approach Stimulates Reverse Cholesterol Transport and Reduces Atherosclerosis in Mice

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Ditiatkovski, Michael ^a   D'Souza, Wilissa ^a   Kesani, Rajitha ^a   Chin Dusting, Jaye ^a   de Haan, Judy B ^a   Remaley, Alan ^b   Sviridov, Dmitri ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A I MIMETIC PEPTIDE; APOLIPOPROTEIN E; CHOLESTEROL; GLUTAMYLLYSYLLEUCYLLYSYLALANYLLYSYLLEUCYLGLUTAMYLGLUTAMYLLEUCYLLYSYLALANYLLYSYLLEUCYLGLUTAMYLGLUTAMYLLEUCYLLEUCYLPROPYLGLUTAMYLLYSYLLEUCYLLYSYLALANYLLYSYLLEUCYLGLUTAMYLGLUTAMYLLEUCYLLYSYLALANYLLYSYLLEUCYLGLUTAMYLGLUTAMYLLEUCYLLEUCINE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; IN VITRO STUDY; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; VASCULITIS;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; BIOMIMETICS; CHOLESTEROL; DISEASE MODELS, ANIMAL; INFLAMMATION; MALE; MICE; MICE, KNOCKOUT; OXIDATION-REDUCTION; PEPTIDES;

MUS;

EID: 84879902998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068802     Document Type: Article

References (36)

1. Murphy AJ, Remaley AT, Sviridov D, (2010) HDL Therapy: Two Kinds of Right? Curr Pharm Des 16: 4134-4147.
2. Osei-Hwedieh DO, Amar M, Sviridov D, Remaley AT, (2011) Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther 130: 83-91.
3. Anantharamaiah GM, Mishra VK, Garber DW, Datta G, Handattu SP, et al. (2007) Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 48: 1915-1923.
4. Getz GS, Wool GD, Reardon CA, (2009) Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action. Curr Opin Lipidol 20: 171-175.
5. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, et al. (2002) Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol. Circulation 105: 290-292.
6. Li X, Chyu K-Y, Neto JRF, Yano J, Nathwani N, et al. (2004) Differential Effects of Apolipoprotein A-I-Mimetic Peptide on Evolving and Established Atherosclerosis in Apolipoprotein E-Null Mice. Circulation 110: 1701-1705.
7. Amar MJA, D'Souza W, Turner S, Demosky S, Sviridov D, et al. (2010) 5A Apolipoprotein Mimetic Peptide Promotes Cholesterol Efflux and Reduces Atherosclerosis in Mice. J Pharmacol Experiment Ther 334: 634-641.
8. Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, et al. (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 51: 1496-1503.
9. Iwata A, Miura S-i, Zhang B, Imaizumi S, Uehara Y, et al. (2011) Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits. Atherosclerosis 218: 300-307.
10. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, et al. (2011) Dysfunctional High-Density Lipoprotein and the Potential of Apolipoprotein A-1 Mimetic Peptides to Normalize the Composition and Function of Lipoproteins. Circulation Journal 75: 1533-1538.
11. Vakili L, Hama S, Kim JB, Tien D, Safarpoor S, et al. (2010) The Effect of HDL Mimetic Peptide 4F on PON1. Adv Exp Med Biol 660: 167-172.
12. Sethi AA, Amar M, Shamburek RD, Remaley AT, (2007) Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 8: 201-212.
13. Zhao W, Du F, Zhang M, Sun S, Yu H, et al. (2011) A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity. Exp Biol Med (Maywood) 236: 1468-1476.
14. Sviridov DO, Ikpot IZ, Stonik J, Drake SK, Amar M, et al. (2011) Helix stabilization of amphipathic peptides by hydrocarbon stapling increases cholesterol efflux by the ABCA1 transporter. Biochem Biophys Res Comm 410: 446-451.
15. Fukushima D, Yokoyama S, Kezdy FJ, Kaiser ET, (1981) Binding of amphiphilic peptides to phospholipid/cholesterol unilamellar vesicles: a model for protein-cholesterol interaction. Proc Natl Acad Sci U S A 78: 2732-2736.
16. D'Souza W, Stonik JA, Murphy A, Demosky SJ, Sethi AA, et al. (2010) Structure/Function Relationships of Apolipoprotein A-I Mimetic Peptides: Implications for Antiatherogenic Activities of High-Density Lipoprotein. Circ Res 107: 217-227.
17. Gaudriault G, Vincent JP, (1992) Selective labeling of alpha- or epsilon-amino groups in peptides by the Bolton-Hunter reagent. Peptides 13: 1187-1192.
18. Warnick GR, Benderson J, Albers JJ, (1982) Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 28: 1379-1388.
19. Sviridov D, Chin-Dusting J, Nestel P, Kingwell B, Hoang A, et al. (2006) Elevated HDL Cholesterol is Functionally Ineffective in Cardiac Transplant Recipients: Evidence for Impaired Reverse Cholesterol Transport. Transplantation 81: 361-366.
20. Low H, Hoang A, Sviridov D (2012) Cholesterol Efflux Assay. J Vis Exp: e3810.
21. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, et al. (2003) Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In Vivo. Circulation 108: 661-663.
22. Mukhamedova N, Escher G, D'Souza W, Tchoua U, Grant A, et al. (2008) Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. J Lipid Res 49: 2312-2322.
23. Choudhury RP, Rong JX, Trogan E, Elmalem VI, Dansky HM, et al. (2004) High-Density Lipoproteins Retard the Progression of Atherosclerosis and Favorably Remodel Lesions Without Suppressing Indices of Inflammation or Oxidation. Arterioscler Thromb Vasc Biol 24: 1904-1909.
24. Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, et al. (2003) Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 44: 828-836.
25. Qin S, Kamanna VS, Lai JH, Liu T, Ganji SH, et al. (2012) Reverse D4F, an Apolipoprotein-AI Mimetic Peptide, Inhibits Atherosclerosis in ApoE-null Mice. J Cardiovasc Pharmacol Ther 17: 334-343.
26. Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, et al. (2001) A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 42: 545-552.
27. Handattu SP, Garber DW, Horn DC, Hughes DW, Berno B, et al. (2007) ApoA-I Mimetic Peptides with Differing Ability to Inhibit Atherosclerosis Also Exhibit Differences in Their Interactions with Membrane Bilayers. J Biol Chem 282: 1980-1988.
28. Nayyar G, Garber DW, Palgunachari MN, Monroe CE, Keenum TD, et al. (2012) Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis 224: 326-331.
29. Nayyar G, Mishra VK, Handattu SP, Palgunachari MN, Shin R, et al. (2012) Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides. J Lipid Res 53: 849-858.
30. Chattopadhyay A, Navab M, Hough G, Gao F, Meriwether D, et al. (2013) A novel approach to oral apoA-I mimetic therapy. J Lipid Res 54: 995-1010.
31. Meriwether D, Imaizumi S, Grijalva V, Hough G, Vakili L, et al. (2011) Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma. J Lipid Res 52: 1795-1809.
32. Navab M, Reddy ST, Anantharamaiah GM, Hough G, Buga GM, et al. (2012) D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in low-density lipoprotein receptor-null mice. J Lipid Res 53: 437-445.
33. Navab M, Reddy ST, Anantharamaiah GM, Imaizumi S, Hough G, et al. (2011) Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res 52: 1200-1210.
34. Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, et al. (2010) ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation. Science 328: 1689-1693.
35. Wool GD, Vaisar T, Reardon CA, Getz GS, (2009) An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J Lipid Res 50: 1889-1900.
36. Handattu SP, Datta G, Epand RM, Epand RF, Palgunachari MN, et al. (2010) Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice. J Lipid Res 51: 3491-3499.